Why a National Drugs Database is important
The question remains, what are the plans to enforce such regulations more stringently?
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s note
Need for introspection beyond brand-building
Because laws are only as good as their enforcement
API manufacturing finally getting the attention it deserves
While formulation generics flounders a bit, the data show that the Indian API industry has done better, with a five-year revenue…
Will FMRAI’s PIL finally prod govt to make UCPMP mandatory?
As COVID-19 continues to extract its price, will a more aware patient pool build up public opinion and turn the tide?
High expectations from the draft Bill
The regulation of all retail channels as proposed by the draft Drugs, Medical Devices and Cosmetics Bill 2022 becomes even more…
India’s medicine watchdog under the scanner once again
Hopefully, this case will initiate as deep a clean up and introspection as the 2012 PCC report
Preparing for surprise inspections
Will surprise site inspections be the end of a long wait? Or the start of another tunnel into noncompliance?
Taking India beyond ‘Pharmacy of the World’
A policy to incentivise pharma R&D is crucial as there are already signs that pharma R&D dives when revenues dip
Will a limited vaccine waiver limit future options?
As attempts to ring-fence markets and restrict access continue, will India and South Africa toe the WTO line?
Still tripping on TRIPS
If India, one of the main proponents of the TRIPS waiver, is left out, is it time for an ‘India waiver’ to show the way forward?
Filling the gaps in India’s pharma manufacturing supply chain
The lessons of the past – of spiralling API costs, overdependence on a shrinking list of API makers – have been well learnt
Why we need an Aatmanirbhar booster strategy
An Aatmanirbhar booster strategy will save lives. As a bonus, it will also boost long term development programmes at local…
With Omicron, the SARS-CoV-2 virus ups the ante
VOCs like Omicron are only to be expected as the divide between the vaccine haves and have-nots, and the Global North-South,…
The Covaxin-WHO EUL saga
Manufacturers will need to cover all bases from the start, as the regulatory process will only get more stringent and competitive
Biocon Biologics-SII alliance should balance business and public health
As both leaders hint at the intangibles of the alliance, let's hope they make good their promise to both patients as well as…
Is India’s pharma sector being penalised for its success?
Leaving out pharma from the RoDTEP scheme is harsh but the message is that managing the COVID-19 situation in India takes…
Not independent, but more inter-dependent than ever before
As India's tryst with destiny and disease continues, our identity as citizens of the same planet connects us all, held ransom by…
PharmEasy-Thyrocare deal milestone for e-pharmacy sector
No longer part of the 'upstart start ups' brigade, it is high time e-pharmacies get their own regulations
Preparing for the third wave
Even if we need global help to meet today's needs, we have to shore up infrastructure for future disruptions
No more the pharmacy/vaccine maker of the world?
India has risen like a phoenix before, but this time, this resilience comes at too high a price